Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Tysabri

Tysabri (humanized monoclonal raised against selected leukocyte integrins) Biogen Idec/Elan Treatment of patients with relapsing forms of MS... [Pg.381]

Natalizumab (Tysabri ) is a recombinant humanized IgG4 mAb that binds to the a4-integrin subunit of a4(31 (VLA-4) and oA M (LPAM-1) integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the a4-mediated adhesion of leukocytes to their respective receptors.103 104 The receptor for a4pi, vascular cell adhesion molecule-1 (VCAM-1), is expressed on activated endothelial cells and is... [Pg.135]

Tysabri Natalizumab Biogen Idee Anti-alpha 4 Multiple sclerosis 2005... [Pg.580]

Interferon-P Mnltiple sclerosis Avonex, Rebif Betaseron, Humira, Tysabri, Copaxone... [Pg.96]

Methylphenidate, Transdermal (Daytrana) Modafinil (Provigil) Natalizumab (Tysabri) Nimodipine (Nimotop) Rivastigmine (Exelon)... [Pg.43]

Tysabri for multiple sclerosis may lead to skin melanoma, and... [Pg.53]

Tysabri Anti-a4 integrin monoclonal Ab Elan Multiple sclerosis 2006... [Pg.69]

Natalizumab (Tysabri), an anti-a4 integrin monoclonal antibody approved for the treatment of multiple sclerosis, was recently withdrawn from the market temporarily due to cases of progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system associated with immunosuppression [32], These cases highlight our incomplete understanding of the immune system and the translation of preclinical results to humans. [Pg.353]

Sheriden C. Third Tysabri adverse case hits drug class. Nat Rev 2005 4 357-8. [Pg.356]

Tysabri natalizumab (2004) Anti-a4 integrin (mAb-IgG4) Multiple sclerosis Cynomolgus monkey (EFD), Guinea pig (F, EFD, PPD)... [Pg.364]

Natal izumab Tysabri Biogen idee Anti-a4-integrin IgG4 Multiple sclerosis 2004... [Pg.593]

Note Before Tysabri can be infused, all prescribers, patients, and infusion sites must be enrolled in the TOUCH Prescribing Program. This is because of the increased risk of developing multifocal leukoencephalopathy. [Pg.403]

Natalizumab Tysabri Biogen Idec/Elan humanized mAb VLA4 multiple sclerosis 2004 lgG4 6-10% ... [Pg.1152]

Tysabri approved package insert. 2008. Available at http //www.tysabri.com. [Pg.197]

See other pages where Tysabri is mentioned: [Pg.125]    [Pg.136]    [Pg.51]    [Pg.232]    [Pg.20]    [Pg.50]    [Pg.232]    [Pg.45]    [Pg.353]    [Pg.445]    [Pg.959]    [Pg.1073]    [Pg.244]    [Pg.594]    [Pg.594]    [Pg.595]    [Pg.782]    [Pg.244]    [Pg.594]    [Pg.594]    [Pg.595]    [Pg.782]    [Pg.403]    [Pg.666]    [Pg.684]    [Pg.194]    [Pg.202]   
See also in sourсe #XX -- [ Pg.232 ]

See also in sourсe #XX -- [ Pg.20 , Pg.53 ]

See also in sourсe #XX -- [ Pg.232 ]

See also in sourсe #XX -- [ Pg.194 , Pg.202 ]

See also in sourсe #XX -- [ Pg.232 ]

See also in sourсe #XX -- [ Pg.352 ]

See also in sourсe #XX -- [ Pg.574 ]



SEARCH



© 2024 chempedia.info